Infinity Pharma and AbbVie ink development deal

AbbVie (NYSE:ABBV) and Infinity Pharmaceuticals (NASDAQ:INFI) enter into a global collaboration to develop and commercialize IPI-145 (duvelisib), an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for the treatment of patients with cancer. Duvelisib has shown clinical activity across a broad range of blood cancers.

Under the terms of the agreement, Infinity will receive an upfront payment of $275M and up to $530M in development, regulatory and commercial milestone payments. Domestically, the companies will jointly commercialize duvelisib and share profits equally. Outside of the U.S. AbbVie will be responsible to all commercialization activities and will pay Infinity royalties on net sales ranging from 23.5 - 30.5%.

From other sites
Comments (1)
  • chi wan
    , contributor
    Comments (2) | Send Message
    great news!
    3 Sep 2014, 09:46 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs